Akero Therapeutics Inc (NASDAQ: AKRO) is 14.95% higher on its value in year-to-date trading and has touched a low of $11.25 and a high of $58.38 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AKRO stock was last observed hovering at around $27.54 in the last trading session, with the day’s loss setting it -0.7%.
Currently trading at $26.84, the stock is -1.26% and 12.57% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.14 million and changing -2.54% at the moment leaves the stock -17.75% off its SMA200. AKRO registered -32.46% loss for a year compared to 6-month loss of -48.62%. The firm has a 200-day simple moving average (SMA200) of -$8.93.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 25.36% gain in the last 1 month and extending the period to 3 months gives it a 20.25%, and is -8.43% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.26% over the week and 10.31% over the month.
Akero Therapeutics Inc (AKRO) has around 56 employees, a market worth around $1.85B and $0.00M in sales. Distance from 52-week low is 138.58% and -54.03% from its 52-week high. The company has generated returns on investments over the last 12 months (-27.05%).
Akero Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$1.The EPS is expected to shrink by -37.28% this year.
Akero Therapeutics Inc (AKRO) Top Institutional Holders
230 institutions hold shares in Akero Therapeutics Inc (AKRO), with institutional investors hold 94.92% of the company’s shares. The shares outstanding are 68.95M, and float is at 59.19M with Short Float at 15.88%. Institutions hold 89.29% of the Float.
The top institutional shareholder in the company is Janus Henderson Group PLC with over 4.43 million shares valued at $206.61 million. The investor’s holdings represent 7.96% of the AKRO Shares outstanding. As of Jun 29, 2023, the second largest holder is Alkeon Capital Management LLC with 3.47 million shares valued at $161.89 million to account for 6.24% of the shares outstanding. The other top investors are Blackrock Inc. which holds 3.32 million shares representing 5.97% and valued at over $155.06 million, while Price (T.Rowe) Associates Inc holds 5.92% of the shares totaling 3.29 million with a market value of $153.59 million.
Akero Therapeutics Inc (AKRO) Insider Activity
The most recent transaction is an insider sale by Cheng Andrew,the company’sPresident and CEO. SEC filings show that Cheng Andrew sold 1,969 shares of the company’s common stock on Mar 13 ’24 at a price of $28.33 per share for a total of $55782.0. Following the sale, the insider now owns 0.59 million shares.
Akero Therapeutics Inc disclosed in a document filed with the SEC on Mar 13 ’24 that White William Richard (Chief Financial Officer) sold a total of 724 shares of the company’s common stock. The trade occurred on Mar 13 ’24 and was made at $28.33 per share for $20511.0. Following the transaction, the insider now directly holds 49630.0 shares of the AKRO stock.
Still, SEC filings show that on Mar 13 ’24, Yale Catriona (Chief Development Officer) disposed off 723 shares at an average price of $28.33 for $20483.0. The insider now directly holds 77,692 shares of Akero Therapeutics Inc (AKRO).
